-$0.13 EPS Expected for Viking Therapeutics Inc (NASDAQ:VKTX) This Quarter

Wall Street analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Viking Therapeutics’ earnings, with estimates ranging from ($0.16) to ($0.09). Viking Therapeutics posted earnings of ($0.07) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 85.7%. The business is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.

According to Zacks, analysts expect that Viking Therapeutics will report full year earnings of ($0.39) per share for the current year, with EPS estimates ranging from ($0.44) to ($0.35). For the next fiscal year, analysts expect that the company will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.78) to ($0.47). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Viking Therapeutics.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.05.

VKTX has been the topic of several research analyst reports. BidaskClub lowered Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday. Svb Leerink reaffirmed an “outperform” rating on shares of Viking Therapeutics in a research note on Thursday, January 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Viking Therapeutics in a research note on Tuesday, November 5th. B. Riley initiated coverage on Viking Therapeutics in a research note on Thursday, November 21st. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Maxim Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Viking Therapeutics in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. Viking Therapeutics presently has an average rating of “Buy” and an average target price of $18.76.

Shares of Viking Therapeutics stock traded up $0.05 during trading on Thursday, reaching $7.42. 195,894 shares of the company’s stock were exchanged, compared to its average volume of 1,040,008. Viking Therapeutics has a 1-year low of $6.15 and a 1-year high of $11.03. The company has a market cap of $531.86 million, a P/E ratio of -18.55 and a beta of 2.31. The firm’s 50-day moving average price is $7.75 and its 200 day moving average price is $7.40.

A number of large investors have recently added to or reduced their stakes in VKTX. Tower Research Capital LLC TRC boosted its stake in Viking Therapeutics by 3,261.8% in the third quarter. Tower Research Capital LLC TRC now owns 8,001 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 7,763 shares in the last quarter. Wedbush Securities Inc. increased its holdings in Viking Therapeutics by 64.1% in the third quarter. Wedbush Securities Inc. now owns 19,207 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 7,500 shares in the last quarter. Alpine Group USVI LLC bought a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $172,000. Brinker Capital Inc. boosted its holdings in shares of Viking Therapeutics by 8.4% during the 3rd quarter. Brinker Capital Inc. now owns 32,672 shares of the biotechnology company’s stock worth $225,000 after buying an additional 2,544 shares in the last quarter. Finally, Creative Planning boosted its holdings in shares of Viking Therapeutics by 11.4% during the 3rd quarter. Creative Planning now owns 44,673 shares of the biotechnology company’s stock worth $307,000 after buying an additional 4,561 shares in the last quarter. 56.43% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Featured Article: Monthly Dividend Stocks

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.